Professor Ken Herrmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Professor ken herrmann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Professor Ken Herrmann Today - Breaking & Trending Today

Theragnostics Strengthens Board of Directors with Key Appointments

Theragnostics Strengthens Board of Directors with Key Appointments
Drug Development Experts Dr Dennis Langer and Professor Ken Herrmann Appointed as Non-Executive Directors
LONDON, Aug. 4, 2021 /PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces today the appointments of Dr Dennis Langer and Professor Ken Herrmann as Non-Executive Directors to its Board.
Dr Dennis Langer has served as a director of both public and private biotechnology, pharmaceutical and diagnostic companies, and has an extensive pharmaceutical company background. He previously served as CEO of Neose Technologies, Inc.; was President of Dr Reddy s North American business; and was Senior Vice President of Research and Development at GlaxoSmithKline plc. He is currently a Director of the Whitehead Institute for Biomedical Research, Myriad Genetics, Inc. (NASDAQ: MYGN) and Brooklyn ImmunoTherapeutics, Inc. (NYSE American: ....

United States , City Of , United Kingdom , Ian Gowrie Smith , Prnewswire Theragnostics , Dennis Langer , Greg Mullen , Drug Development Experts Dr Dennis Langer , University Of California Los Angeles , Harvard Law School , Whitehead Institute For Biomedical Research , Brooklyn Immunotherapeutics Inc , Columbia University , Genetics Inc , Georgetown University School Of Medicine , Department Of Nuclear Medicine At Universit , Department Of Nuclear Medicine , Neose Technologies Inc , Professor Ken Herrmann Appointed , Professor Ken Herrmann , Non Executive Directors , Neose Technologies , North American , Senior Vice President , Whitehead Institute , Biomedical Research ,

New Drug Targets Treatment-Resistant Prostate Cancers and Prolongs Trial Participants' Lives

New Drug Targets Treatment-Resistant Prostate Cancers and Prolongs Trial Participants' Lives
technologynetworks.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technologynetworks.com Daily Mail and Mail on Sunday newspapers.

City Of , United Kingdom , Peter Albers , Ken Herrmann , National Institute For Health , European Association Of Urology , Scientific Office , Institute Of Cancer Research , Head Of The Department Urology , Dusseldorf University , European Association , Johann De Bono , Experimental Cancer Medicine , Cancer Research , Consultant Medical Oncologist , Royal Marsden , Professor Ken Herrmann , Nuclear Medicine , University Hospital Essen , National Institute , Care Excellence , Professor Peter Albers , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , பீட்டர் ஆல்பர்ஸ் , கேன் ஹெர்மன் ,

New concept drug hunts down late-stage prostate cancer

E-Mail
A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.
Despite progress in medicine in recent years, metastatic castration-resistant prostate cancer remains untreatable and fatal. The new treatment, known as Lu-PSMA-617, takes a new approach, targeting a molecule called PSMA, which is known to be increased on the surfaces of the tumour cells, destroying them and their surrounding microenvironment. ....

City Of , United Kingdom , Peter Albers , Ken Herrmann , National Institute For Health , European Association Of Urology , Scientific Office , Institute Of Cancer Research , Head Of The Department Urology , Dusseldorf University , European Association , Johann De Bono , Experimental Cancer Medicine , Cancer Research , Consultant Medical Oncologist , Royal Marsden , Professor Ken Herrmann , Nuclear Medicine , University Hospital Essen , National Institute , Care Excellence , Professor Peter Albers , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , பீட்டர் ஆல்பர்ஸ் , கேன் ஹெர்மன் ,